Top Markets
Coin of the day
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
株式のランク #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
株価
$1.73
最終同期: 2025-06-17
時価総額
$2.55M
変化(1日)
-0.29%
変化(1年)
0.00%
US
取引 Eiger BioPharmaceuticals, Inc. (EIGR)

カテゴリー

Eiger BioPharmaceuticals, Inc.(EIGR)の株価履歴
終値の最高値: $1.73 (2025-06-01)

終値の最安値: $3.75K (2014-01-01)
Eiger BioPharmaceuticals, Inc. の株価履歴(2014 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2025 -31.11%
2024 -68.15%
2023 -86.27%
2022 -65.86%
2021 -43.34%
2020 -27.82%
2019 28.55%
2018 -15.78%
2017 8.44%
2016 -45.90%
2015 -91.44%
2014 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE